Published in Cancer Gene Ther on January 03, 2014
ROR functions as a ceRNA to regulate Nanog expression by sponging miR-145 and predicts poor prognosis in pancreatic cancer. Oncotarget (2016) 0.91
Paracrine factors from adipose-mesenchymal stem cells enhance metastatic capacity through Wnt signaling pathway in a colon cancer cell co-culture model. Cancer Cell Int (2015) 0.88
New targeted therapies in pancreatic cancer. World J Gastroenterol (2015) 0.87
A concise review on the current understanding of pancreatic cancer stem cells. J Cancer Stem Cell Res (2015) 0.82
Emerging roles of microRNAs in pancreatic cancer diagnosis, therapy and prognosis (Review). Int J Oncol (2015) 0.81
Viro-immune therapy: A new strategy for treatment of pancreatic cancer. World J Gastroenterol (2016) 0.77
Molecular and Cellular Interactions of Allogenic and Autologus Mesenchymal Stem Cells with Innate and Acquired Immunity and Their Role in Regenerative Medicine. Int J Hematol Oncol Stem Cell Res (2017) 0.75
cDNA microarray analysis of the effect of cantharidin on DNA damage, cell cycle and apoptosis-associated gene expression in NCI-H460 human lung cancer cells in vitro. Mol Med Rep (2015) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
The hallmarks of cancer. Cell (2000) 113.05
Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38
Multilineage potential of adult human mesenchymal stem cells. Science (1999) 66.19
Stem cells, cancer, and cancer stem cells. Nature (2001) 50.27
Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy (2006) 37.55
Wnt/beta-catenin signaling in development and disease. Cell (2006) 30.09
Upstream and downstream of mTOR. Genes Dev (2004) 21.61
Pluripotency of mesenchymal stem cells derived from adult marrow. Nature (2002) 19.57
Wnt signalling in stem cells and cancer. Nature (2005) 19.26
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med (2011) 18.99
Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell (2009) 18.31
Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med (1986) 17.64
Cellular survival: a play in three Akts. Genes Dev (1999) 17.05
Cancer statistics, 2004. CA Cancer J Clin (2004) 15.72
Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood (2004) 13.79
Mesenchymal stem cells in health and disease. Nat Rev Immunol (2008) 11.14
Mesenchymal stem cells. J Orthop Res (1991) 10.98
Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity (1995) 10.59
WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet (2004) 10.38
Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell (1988) 10.29
Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood (2002) 9.40
Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci (2006) 8.09
Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell (2008) 7.47
Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol (2001) 7.43
Immunomodulatory properties of mesenchymal stromal cells. Blood (2007) 6.97
Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med (2006) 6.77
Integration of Notch and Wnt signaling in hematopoietic stem cell maintenance. Nat Immunol (2005) 6.49
Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res (2004) 6.49
Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res (2004) 6.34
Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem (1996) 6.22
Gastric cancer originating from bone marrow-derived cells. Science (2004) 6.04
Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood (2004) 6.02
Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation (1968) 5.52
Notch signalling regulates stem cell numbers in vitro and in vivo. Nature (2006) 5.49
Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res (2001) 5.48
Why are MSCs therapeutic? New data: new insight. J Pathol (2009) 5.25
Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res (2005) 5.17
Human mesenchymal stem cells modulate B-cell functions. Blood (2005) 5.12
Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res (2002) 4.99
PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol (2009) 4.83
Mesenchymal stromal cells: current understanding and clinical status. Stem Cells (2010) 4.79
Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer (2002) 4.76
Directed migration of neural stem cells to sites of CNS injury by the stromal cell-derived factor 1alpha/CXC chemokine receptor 4 pathway. Proc Natl Acad Sci U S A (2004) 4.70
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature (2011) 4.61
Progression model for pancreatic cancer. Clin Cancer Res (2000) 4.60
Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle (2003) 4.55
Osteogenesis in transplants of bone marrow cells. J Embryol Exp Morphol (1966) 4.55
Apoptosis control by death and decoy receptors. Curr Opin Cell Biol (1999) 4.54
Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg (1996) 4.51
Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood (2003) 4.43
The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer (2008) 4.42
Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci U S A (1996) 4.39
Comparison of human stem cells derived from various mesenchymal tissues: superiority of synovium as a cell source. Arthritis Rheum (2005) 4.25
Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood (2004) 4.03
The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer (2007) 4.01
From the laboratory bench to the patient's bedside: an update on clinical trials with mesenchymal stem cells. J Cell Physiol (2007) 3.87
Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J Exp Med (2006) 3.81
PI 3-kinase, Akt and cell survival. Semin Cell Dev Biol (2004) 3.57
IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol (2008) 3.53
Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci (2009) 3.39
KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res (1988) 3.31
Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther (2005) 3.27
KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer (2010) 3.27
Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica (2005) 3.11
Epithelial-mesenchymal transition: a cancer researcher's conceptual friend and foe. Am J Pathol (2009) 3.09
Cell surface and transcriptional characterization of human adipose-derived adherent stromal (hADAS) cells. Stem Cells (2005) 2.90
Treatment of neural injury with marrow stromal cells. Lancet Neurol (2002) 2.89
Migration of bone marrow and cord blood mesenchymal stem cells in vitro is regulated by stromal-derived factor-1-CXCR4 and hepatocyte growth factor-c-met axes and involves matrix metalloproteinases. Stem Cells (2006) 2.85
Tumor microenvironment: the role of the tumor stroma in cancer. J Cell Biochem (2007) 2.81
Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells (2005) 2.80
Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med (1999) 2.76
Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells (2009) 2.68
Ras signalling and apoptosis. Curr Opin Genet Dev (1998) 2.63
Circulating skeletal stem cells. J Cell Biol (2001) 2.58
A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res (2007) 2.57
Isolation of human multipotent mesenchymal stem cells from second-trimester amniotic fluid using a novel two-stage culture protocol. Hum Reprod (2004) 2.54
Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Invest (1992) 2.54
TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol (2007) 2.49
Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci U S A (2009) 2.47
Mesenchymal stem cells: a new strategy for immunosuppression and tissue repair. Cell Res (2010) 2.46
Stabilization of beta-catenin impacts pancreas growth. Development (2006) 2.44
Beta-catenin is essential for pancreatic acinar but not islet development. Development (2005) 2.38
The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. Oncogene (2004) 2.35
Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications. Stem Cell Res Ther (2010) 2.29
Characterization and functionality of cell surface molecules on human mesenchymal stem cells. J Biomed Sci (2003) 2.22
Mesenchymal stem cells: progress toward promise. Cytotherapy (2005) 2.19
Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. J Immunol (2009) 2.15
Epidemiology of pancreatic cancer. Minerva Chir (2004) 2.14
Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs. J Exp Med (1999) 2.13
PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs (2005) 2.09
The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells. Proc Natl Acad Sci U S A (2009) 2.07
The KRAS oncogene: past, present, and future. Biochim Biophys Acta (2005) 2.05
The growth inhibitory effect of mesenchymal stem cells on tumor cells in vitro and in vivo. Cancer Biol Ther (2007) 2.05
Overexpression of HER2/neu oncogene in human pancreatic carcinoma. Hum Pathol (1993) 2.05
Inhibition of the phosphatidylinositol 3'-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther (2002) 2.03
Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med (1998) 2.03
The epithelial mesenchymal transition confers resistance to the apoptotic effects of transforming growth factor Beta in fetal rat hepatocytes. Mol Cancer Res (2002) 2.01
Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. Clin Cancer Res (2007) 1.97